Strain Imaging in Breast Cancer Patients Receiving Trastuzumab

Completed

Conditions studied: Her 2 Positive Breast Cancer

In brief

The purpose of this research study is to evaluate the effects of the chemotherapeutic drug, Trastuzumab (Herceptin) on the heart. Trastuzumab (Herceptin) is used to treat specific types of breast cancer and is known to cause weakening of the heart. Unfortunately, little is know as to why this this happens. The investigators want to identify any factors that may lead to the early detection, treatment and prevention of the cardiotoxicity (heart problem) associated with this drug.

Key facts

Study ID

NCT02080390

Run by

University of Florida

People needed

25

Starts

2014-09-01

Expected to finish

2019-02-14

Last updated by the study team

2019-03-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age greater than 18 years
• Her 2 positive breast cancer.
• Patients who are currently receiving Trastuzumab (Herceptin).
• Patients who received Trastuzumab (Herceptin) after the formation of the UFHealth Medical Plaza pharmacy database was initiated.

You may not qualify if…

• Age less than 18 years
• Patients who have not received Trastuzumab (Herceptin).
• Patients who received Trastuzumab prior to the formation of the UFHealth Medical Plaza pharmacy database.

Where it is running

• Univerisity of Florida — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.